Amarin Corporation reported a 7% increase in total net revenue for Q1 2026, reaching $45.1 million, led by higher international sales and licensing revenue. The company achieved positive cash flow for the second consecutive quarter and expects full-year positive cash flow in 2026. Operating expenses declined by 31% due to restructuring and cost optimization, narrowing the operating loss to $11.3 million from $16.8 million a year earlier. Amarin's U.S. market remains resilient with increased branded prescriptions, while its European partnership with Recordati shows promising growth. Updated clinical guidelines supporting Amarin's cardiovascular therapy further strengthen its market position.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
